← All trials
NCT04382352
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2019
- Primary completion
- May 28, 2020
- Completion date
- Mar 28, 2021
- First posted
- May 11, 2020
- Last posted
- May 11, 2020
- Enrollment
- 19
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai Pharmaceuticals Holding Co., LtdLead sponsor
- Fudan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.